OBJECTIVE: We undertook a prospective cohort study to ascertain the risk factors for the development of squamous intraepithelial lesions (SIL) in patients with systemic lupus erythematosus (SLE). METHODS: One hundred thirty-seven SLE patients with a normal Papanicolaou (Pap) smear at baseline were evaluated at 6-month intervals for up to 3 years. At each visit, a Pap smear, human papillomavirus (HPV) DNA test, and clinical assessment were performed. RESULTS: Among the 137 patients, there were 12 incident cases (8.8%) of SIL over a median followup duration of 30.7 months (interquartile range 25.5-31.7). Among the 30 patients with HPV infection detectable by DNA testing at baseline, 9 (30%) developed SIL. The independent risk factors for the incident SIL in this group of SLE patients included the use of cyclophosphamide (CYC) ever (odds ratio [OR] 5.6, 95% confidence interval [95% CI] 1.1-29.3; P=0.041) and persistent high-risk HPV infection (OR 26.9, 95% CI 3.2-222.3; P=0.002). The use of baseline HPV testing has a higher sensitivity than abnormal cytology (defined as atypical squamous cells of undetermined significance; 47.7% versus 33.3%) in predicting the development of SIL. CONCLUSION: Independent risk factors associated with the development of SIL in SLE patients included persistent high-risk HPV infection and the use of CYC. Low-risk patients who receive negative test results on both cervical cytology screening and HPV DNA testing may not need to be rescreened within 3 years.
OBJECTIVE: We undertook a prospective cohort study to ascertain the risk factors for the development of squamous intraepithelial lesions (SIL) in patients with systemic lupus erythematosus (SLE). METHODS: One hundred thirty-seven SLEpatients with a normal Papanicolaou (Pap) smear at baseline were evaluated at 6-month intervals for up to 3 years. At each visit, a Pap smear, human papillomavirus (HPV) DNA test, and clinical assessment were performed. RESULTS: Among the 137 patients, there were 12 incident cases (8.8%) of SIL over a median followup duration of 30.7 months (interquartile range 25.5-31.7). Among the 30 patients with HPV infection detectable by DNA testing at baseline, 9 (30%) developed SIL. The independent risk factors for the incident SIL in this group of SLEpatients included the use of cyclophosphamide (CYC) ever (odds ratio [OR] 5.6, 95% confidence interval [95% CI] 1.1-29.3; P=0.041) and persistent high-risk HPV infection (OR 26.9, 95% CI 3.2-222.3; P=0.002). The use of baseline HPV testing has a higher sensitivity than abnormal cytology (defined as atypical squamous cells of undetermined significance; 47.7% versus 33.3%) in predicting the development of SIL. CONCLUSION: Independent risk factors associated with the development of SIL in SLEpatients included persistent high-risk HPV infection and the use of CYC. Low-risk patients who receive negative test results on both cervical cytology screening and HPV DNA testing may not need to be rescreened within 3 years.
Authors: Seoyoung C Kim; Robert J Glynn; Edward Giovannucci; Sonia Hernández-Díaz; Jun Liu; Sarah Feldman; Elizabeth W Karlson; Sebastian Schneeweiss; Daniel H Solomon Journal: Ann Rheum Dis Date: 2014-03-11 Impact factor: 19.103
Authors: May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke Journal: Best Pract Res Clin Rheumatol Date: 2017-11-10 Impact factor: 4.098
Authors: Seoyoung C Kim; Sebastian Schneeweiss; Jun Liu; Elizabeth W Karlson; Jeffrey N Katz; Sarah Feldman; Daniel H Solomon Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995
Authors: Hjalmar Wadström; Elizabeth V Arkema; Christopher Sjöwall; Johan Askling; Julia F Simard Journal: Rheumatology (Oxford) Date: 2017-04-01 Impact factor: 7.580
Authors: Shui-Lian Yu; Paul K S Chan; Chun-Kwok Wong; Cheuk-Chun Szeto; Suzanne C Ho; Karine So; May M Y Yu; So-Fan Yim; Tak-Hong Cheung; Martin C S Wong; Jo L K Cheung; Apple C M Yeung; Edmund K Li; Lai-Shan Tam Journal: Arthritis Res Ther Date: 2012-04-18 Impact factor: 5.156
Authors: Georgios Nikolakis; Ioannis Karagiannidis; Vasiliki A Zampeli; Andreas Altenburg; Martina Brunner; Christos C Zouboulis Journal: Case Rep Dermatol Date: 2015-11-19